AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01255254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival scaling
Description: Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
Study NCT03455998 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Study NCT01817322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose of Myfortic and Reduced Dose of Myfortic
Description: Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
Study NCT01817322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Dose of Myfortic and Reduced Dose of Myfortic
Description: Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
Study NCT01817322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
Description: 500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
Study NCT01817322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
Description: 500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
Study NCT01817322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab injected both control group and experimental group
Description: The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
Study NCT01817322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab injected both control group and experimental group
Description: The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
Study NCT02857075 — intervention group
Intervention type: OTHER
Intervention: Blood donation
Description: Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
Study NCT03325790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg SPI-1005 BID
Description: Active: low dose
Study NCT03325790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg SPI-1005 BID
Description: Active: high dose
Study NCT03325790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02080962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Gy in 5 fractions
Description: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
Study NCT02080962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 40 Gy in 10 fractions
Description: tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
Study NCT01682551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Medicine
Description: The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day.
Study NCT01682551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Medicine
Description: The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day.
Study NCT01144455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemzar (Gemcitabine)
Description: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
Study NCT01682551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetalozamide
Description: If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang.
Study NCT02666664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Study NCT02666664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Study NCT03880253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Placebo or CTP-692
Study NCT01144455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Study NCT01144455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: 340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Study NCT02131064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV infusion at a dose to achieve an AUC of 6 mg\*min/mL q3w
Study NCT02131064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 IV infusion q3w
Study NCT02131064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
Study NCT02131064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
Study NCT02131064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
Study NCT02131064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
Study NCT01062893 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile normal saline 0 mls
Description: at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
Study NCT01062893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15 mls sterile normal saline
Description: After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
Study NCT03975257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device: Ectoin Lozenge
Description: Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
Study NCT01820520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brilliant blue G
Description: Double staining with brilliant blue G 0.025% for macular surgery
Study NCT03231124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: LEO 32731 is being developed by LEO Pharma.
Study NCT03231124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration, only lacking LEO 32731
Study NCT00581893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
Study NCT00581893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT03270410 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care.
Study NCT01848613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT04220398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with hormone therapy
Description: Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
Study NCT04220398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant hormone therapy
Description: HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
Study NCT04220398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy (RP)+ extended lymph node dissection
Description: Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery.
Study NCT04220398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy (RP)+ extended lymph node dissection
Description: Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery.
Study NCT04220398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical Prostatectomy (RP)+ extended lymph node dissection
Description: Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery.
Study NCT01504776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
Study NCT01504776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT03235700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal hyperemia with adenosine followed by nicorandil
Description: IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
Study NCT03235700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal hyperemia with nicorandil followed by adenosine
Description: IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
Study NCT02550938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign
Description: The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
Study NCT00953771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
Study NCT03063151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Surface Electromyography (EMG)
Study NCT02224404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Gelling Dressing (Exufiber)
Study NCT00660322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Asthma Program
Description: The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~1. Using asthma controller medications as prescribed~2. Having and Asthma Action Plan available to all who may need it.~3. Using asthma rescue medications with the child's first symptoms.~4. Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year.
Study NCT03085836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets.
Study NCT03274115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLI (Blue Laser Imaging)
Description: Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
Study NCT04491877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 1
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal
Study NCT04491877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine formulation 2
Description: Pharmaceutical form: Suspension of virus Route of administration: Intranasal
Study NCT04491877 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Suspension Route of administration: Intranasal
Study NCT02084758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplementation
Description: 7 days of supplementation with sodium nitrate solution
Study NCT02084758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate supplementation
Description: 7 days of supplementation with sodium nitrate solution
Study NCT02084758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo supplementation
Description: 7 days of supplementation with sodium chloride solution
Study NCT02084758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: 7 days of supplementation with sodium chloride solution
Study NCT03620539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Sauna bathing
Study NCT02436291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURE-EX device
Description: Treatment with CURE-EX device twice daily for 24-30 weeks.
Study NCT01857375 — intervention group
Intervention type: DEVICE
Intervention: Insulin Pen Device
Description: Insulin pen was compared to administration of insulin using standard syringes.
Study NCT00688129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KITS Program
Description: This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
Study NCT00876824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Lipid emulsion
Description: Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
Study NCT00876824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
Study NCT02912390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerclage
Description: Macdonald cerclage placed in standard fashion
Study NCT02912390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectant management
Description: placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
Study NCT04267965 — intervention group
Intervention type: PROCEDURE
Intervention: parathyroidectomy plus bilateral thymectomy and autotransplantation
Description: Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
Study NCT03459872 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Alternative medicine therapeutic intervention
Study NCT03459872 — intervention group
Intervention type: DEVICE
Intervention: RU-Fit
Description: FDA approved medical device for the measurement of fine motor control
Study NCT00954889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
Study NCT00954889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: (tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
Study NCT02779114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control group
Description: Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
Study NCT02779114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reduction group 1
Description: Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
Study NCT02779114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reduction group 2
Description: Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
Study NCT05959798 — intervention group
Intervention type: PROCEDURE
Intervention: High power short duration ablation
Description: Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
Study NCT04756076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metal level measurements
Description: Measure multiple metal levels
Study NCT00615875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
Study NCT00615875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
Study NCT01941173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT01941173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01941173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01941173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT03344211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO